| Heading: |
Tranexamic Acid |
| Question ID: |
1744889 |
| UIN: |
16445 |
| House: |
Commons |
| Date tabled: |
2024-11-26 |
| Asking Member ID: |
5321 |
| Asking Member display name: |
Mr Paul Kohler
|
| Asking Member handle: |
PaulKohlerSW19
|
| Asking Member Twitter reference: |
@PaulKohlerSW19
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of making Tranexamic Acid (TXA) a Schedule 19 Drug. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2024-12-04 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Discussions on the administration of tranexamic acid (TXA) formed part of the Manchester Arena Inquiry, established in 2019, to investigate the deaths of the victims of the attack on the Arena on 22 May 2017. One of the inquiry’s recommendations tasked th... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |